ArticleMolecular medicine (Cambridge, Mass.)2020
Cardioprotective effects of genetically engineered cardiac stem cells by spheroid formation on ischemic cardiomyocytes.
Article in Molecular medicine (Cambridge, Mass.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Safety and Regenerative Properties of Immortalized Human Mesenchymal Stromal Cell Secretome.International journal of molecular sciences · 2025Article
- Reinforcing Stromal Cell Spheroid Through Red-Light Preconditioning for Advanced Vascularization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Generation and applications of cardiac spheroids.npj biomedical innovations · 2025Review
- Quercetin in Shengxian Decoction exhibits anti-ferroptosis protective roles in a myocardial infarction modelFrontiers in pharmacology · 2025Article
- Practical Use of Immortalized Cells in Medicine: Current Advances and Future Perspectives.International journal of molecular sciences · 2023Review
- Therapeutic strategies of three-dimensional stem cell spheroids and organoids for tissue repair and regeneration.Bioactive materials · 2023Review
- 3-Dimensional Bioprinting of Cardiovascular Tissues: Emerging Technology.JACC. Basic to translational science · 2021Review
- Considerations to Model Heart Disease in Women with Preeclampsia and Cardiovascular Disease.Cells · 2021Review
- Unravelling the Biology of Adult Cardiac Stem Cell-Derived Exosomes to Foster Endogenous Cardiac Regeneration and Repair.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSca-1+ cardiac stem cells and their limited proliferative potential were major limiting factors for use in various studies.
methodsTherefore, the effects of sphere genetically engineered cardiac stem cells (S-GECS) inserted with telomerase reverse transcriptase (TERT) were investigated to examine cardiomyocyte survival under hypoxic conditions. GECS was obtained from hTERT-immortalized Sca-1+ cardiac stem cell (CSC) lines, and S-GECS were generated using poly-HEMA.
resultsThe optimal conditions for S-GECS was determined to be 1052 GECS cells/mm
conclusionsOur findings suggest that paracrine factors secreted from transplanted cells may protect host cardiomyoblasts in the infarcted myocardium, contributing to beneficial left ventricle (LV) remodeling after acute myocardial infarction (AMI).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.